Resectability of bilobar liver tumours after simultaneous portal and hepatic vein embolization versus portal vein embolization alone: meta-analysis. Issue 6 (24th November 2022)

• Record Type: Journal Article
• Authors: Korenblik, Remon; van Zon, Jasper F J A; Olij, Bram; Heil, Jan; Dewulf, Maxime J L; Neumann, Ulf P; Olde Damink, Steven W M; Binkert, Christoph A; Schadde, Erik; van der Leij, Christiaan; van Dam, Ronald M
• Is Part Of: BJS open. Volume 6:Issue 6(2022)
• Publication Date: 2022-11-24
• Subjects: Surgery -- Periodicals; 617.005
• DOI: 10.1093/bjsopen/zrac141
• Languages: English
• ISSNs: 2474-9842

Abstract

Abstract: Background: Many patients with bi-lobar liver tumours are not eligible for liver resection due to an insufficient future liver remnant (FLR). To reduce the risk of posthepatectomy liver failure and the primary cause of death, regenerative procedures intent to increase the FLR before surgery. The aim of this systematic review is to provide an overview of the available literature and outcomes on the effectiveness of simultaneous portal and hepatic vein embolization (PVE/HVE) versus portal vein embolization (PVE) alone. Methods: A systematic literature search was conducted in PubMed, Web of Science, and Embase up to September 2022. The primary outcome was resectability and the secondary outcome was the FLR volume increase. Results: Eight studies comparing PVE/HVE with PVE and six retrospective PVE/HVE case series were included. Pooled resectability within the comparative studies was 75 per cent in the PVE group ( n = 252) versus 87 per cent in the PVE/HVE group ( n = 166, OR 1.92 (95% c.i., 1.13–3.25)) favouring PVE/HVE ( P = 0.015). After PVE, FLR hypertrophy between 12 per cent and 48 per cent (after a median of 21–30 days) was observed, whereas growth between 36 per cent and 67 per cent was reported after PVE/HVE (after a median of 17–31 days). In the comparative studies, 90-day primary cause of death was similar between groups (2.5 per cent after PVE versus 2.2 per cent after PVE/HVE), but a higher 90-day primary cause of death was reported in single-arm PVE/HVE cohort studies (6.9 per cent, 12 of 175 patients). Conclusion: Based on moderate/weak evidence, PVE/HVE seems to increase resectability of bi-lobar liver tumours with a comparable safety profile. Additionally, PVE/HVE resulted in faster and more pronounced hypertrophy compared with PVE alone. Abstract : A systematic literature search was conducted to compare the effectiveness of simultaneously performed portal and hepatic vein embolization (PVE/HVE) and PVE alone. Eight observational comparative and six PVE/HVE case series were included. PVE/HVE results in a higher resectability rate and is more effective for future liver remnant growth.